Life Sciences & MedTech Companies: Managing FX When You Enter the US

Florida is home to approximately 6,700 life sciences Florida companies employing around 100,000 people — and the sector is growing. For European and international life sciences and MedTech businesses establishing US operations, Florida offers a compelling combination of research infrastructure, clinical trial networks, and access to the world’s largest healthcare market.

But the financial complexity of international life sciences operations is significant. Clinical trial payments, R&D reimbursements, regulatory fees, equipment procurement from global suppliers, and profit repatriation all create multi-currency exposure that, if unmanaged, erodes margins that are already under pressure in a capital-intensive sector.

The FX challenges specific to life sciences and MedTech

Clinical trial and research payments

Multi-site clinical trials frequently involve payments across five to fifteen jurisdictions simultaneously — investigators, CROs, IRBs, and patient recruitment vendors in multiple countries and currencies. Managing these through a standard bank account means multiple wire fees, retail FX spreads on every conversion, and no visibility over the total currency exposure of a single trial.

Equipment and supply chain payments

Medical device manufacturers and diagnostics companies typically source components, materials, and specialist equipment from global suppliers. A company manufacturing in Florida but sourcing precision parts from Germany, Switzerland, or Japan has ongoing EUR, CHF, and JPY exposure that needs active management rather than ad-hoc conversion.

Regulatory and licensing fees

FDA submission fees, patent filings, and international regulatory compliance costs are denominated in USD for US operations but often must be funded from non-USD accounts. The timing of these payments can also be inflexible — you cannot delay an FDA filing because the exchange rate is unfavourable.

Repatriation of US revenue

For companies whose US subsidiary generates USD revenue but whose parent entity holds costs in GBP, EUR, or another currency, the repatriation decision is a recurring FX event. Made poorly — reactively, at market rates, without forward planning — it introduces unnecessary volatility into reported earnings.

Three FX principles for life sciences companies entering the US

• Separate your payment flows by type. Recurring operational payments (supplier invoices, payroll, regular repatriation) should be handled differently from large one-off payments (equipment purchases, licensing deals). Forward contracts work well for predictable recurring flows; spot transactions may be appropriate for one-offs.
• Build FX review into your budget cycle. For life sciences Florida businesses budgeting clinical trial costs in one currency and executing them in another, the exchange rate assumption embedded in your budget should be reviewed quarterly. A 5% move in EUR/USD can materially affect a trial’s cost basis.
• Centralise visibility before you centralise control. The first step is not to restructure your payment flows — it is to understand them. A consolidated view of all currency inflows and outflows, by currency pair, by volume, by frequency, tells you where the real exposure sits.

How Nextpay Global supports life sciences Florida companies

We work with life sciences Florida and MedTech companies across the US to build payment infrastructure that matches the complexity of the sector. Our platform supports multi-currency accounts, forward contracts, and international payments across 40+ currencies — backed by Corpay‘s global network of 100+ correspondent banks.

For life science Florida companies in the research and trial phase, we help structure payment workflows that reduce the administrative burden of multi-jurisdiction disbursements. For companies in commercial operations, we focus on protecting the margin between USD revenue and home-currency costs.

Our Free FX Review is the right starting point for life sciences Florida companies — a platform demonstration and benchmarking session that shows you exactly where your current FX arrangements are costing you, and what a more efficient structure would look like for your specific operations.